Pharmacist-led, GPhC-regulated weight management. Free pre-screening, written quote before payment, monthly clinician reviews included — from £150 / month.
Enter your height, weight and chosen treatment for an indicative BMI, eligibility and projected weight at 3 / 6 / 12 months. A clinician makes the final decision after reviewing your pre-screening form.
Mounjaro (tirzepatide) averaged ~21% body-weight loss at 72 wks in SURMOUNT-1. Wegovy (semaglutide 2.4 mg) averaged ~15% at 68 wks in STEP-1.
Projections are trial-average estimates assuming you reach and maintain the therapeutic dose alongside lifestyle change. Individual results vary. BMI alone doesn't determine eligibility — your clinician weighs comorbidities, history and contraindications. Not suitable in pregnancy, type-1 diabetes, MEN-2, or a personal/family history of medullary thyroid cancer.
Your monthly fee covers the branded pen, the clinician review and ongoing titration support. Dosing is personalised by your clinician and may step up every 4 weeks when tolerated.
Trial average: ~21% body-weight loss at 72 weeks (SURMOUNT-1).
Trial average: ~15% body-weight loss at 68 weeks (STEP-1).
From the moment you submit the form to your monthly review — here’s the path.
GPhC-regulated questionnaire · ~4 minutes online.
You’re emailed back with next steps — via secure email reminders, never SMS.
In-branch or video · BMI, history & goals reviewed · 15–20 mins.
Collect at Botley or Summertown. Secure email reminders for every follow-up appointment.
Family-run since 2021 — not an online-only chain. Every weight-management decision is reviewed by one of our GPhC-registered pharmacists, here in Oxford.
[Pharmacist Name]
Lead Independent Prescriber
GPhC reg: 2XXXXXX[Pharmacist Name]
Clinical Pharmacist
GPhC reg: 2XXXXXX[Pharmacist Name]
Weight-management Lead
GPhC reg: 2XXXXXXTrial averages for patients staying on the therapeutic dose alongside lifestyle change. Personal trajectory depends on titration tolerance, starting BMI and adherence.
Typically adults with a BMI of 30+ (or 27+ with a weight-related condition such as high blood pressure, pre-diabetes, type-2 diabetes, sleep apnoea or dyslipidaemia). Your clinician confirms after reviewing your pre-screening form.
All clinical correspondence and follow-up appointment reminders are sent via secure email — never by SMS or text alerts. This keeps your medical information protected and gives you a written audit trail of every clinical decision.
Mounjaro (tirzepatide) showed the largest average weight loss in trials (~21% at 72 weeks) but starts higher on monthly cost. Wegovy (semaglutide 2.4 mg) is well-established with ~15% average loss at 68 weeks. Your clinician weighs tolerability, cost, goals and any contraindications with you.
The branded pen, the monthly clinician review, all titration decisions, side-effect support and collection at Botley or Summertown. No starter-kit surcharge, no GP referral fee.
GLP-1 therapy is not suitable in pregnancy or breastfeeding, type-1 diabetes, active gallbladder or pancreatic disease, MEN-2, or personal/family history of medullary thyroid cancer. Your clinician screens for these and other interactions before prescribing.
MediPill’s private weight loss clinic in Oxford prescribes Mounjaro (tirzepatide) and Wegovy (semaglutide) GLP‑1 injections under a UK‑registered pharmacist clinician. We collect at Botley or Summertown and serve patients across Headington, Deddington and the wider Oxfordshire area — monthly clinician reviews, full titration support, secure email follow-ups and no GP referral fee.